Thank you

This live web event has ended. Thank you for attending.

Description

Optimizing the management of patients
with solid tumors using a tumor informed approach for molecular residual
disease assessment and monitoring

Why should you register now for this webinar?
Hear national thought leaders discuss the rapidly evolving role of circulating
tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and
treatment response monitoring.
Brought to you by: CAP TODAY
Moderated by: Bob McGonnagle
Presenters: Noam Z. Drazin, MD, and Gregory Botta, MD, PhD

What will this webinar empower you to do?
Identify common challenges physicians face when managing their patients
with solid tumors
Evaluate how a tumor-informed approach may help stratify high-risk patients
and inform adjuvant treatment decisions
Review recently presented data from the largest “real world” cohort of CRC patients
Ask questions to our distinguished presenters

CAP TODAY does not endorse any of the products or services named within.
The webinar is made possible by a special educational grant from Natera.